2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 295

Ex Vivo Induced Neutrophil Extracellular Traps Are Intrinsically Different in Anca-Associated Vasculitis and Systemic Lupus Erythematosus

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 70

Excessive Cyclic Compressive Stress Increases Susceptibility to IL-1 in 3D-Cultured Chondrocytes

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling

9:00AM-11:00AM: Abstract Number: 293

Expanded Therapeutic ACPA Utility for Different NET-Driven Human (Autoimmune) Diseases

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 118

Experiences and Perceptions of Patients with Rheumatoid Arthritis Participating in an Online Support Group: The Use of Social Media

ARHP Education Poster

9:00AM-11:00AM: Abstract Number: 418

Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 125

Exposure to Passive Smoking and RA Risk; Results from a Swedish Case-Control Study

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 505

Exposure-Response Analyses of the Effect of Upadacitinib on ACR Responses in the Phase 2b Rheumatoid Arthritis Trials in Patients with Inadequate Response to Methotrexate or to Anti-Tumor Necrosis Factor Therapy

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 817

Extension of Affected Vascular Territories in Secondary Aortitis Is Associated to Different Clinical Subtypes?

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 387

F4/80hi Synovial Macrophages in the Pathogeneses of Spontaneous Inflammatory Arthritis in CD11c-Flip-KO (HUPO) Mice

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 584

Factors Associated with the “Bamboo Spine” Phenotype – Data from the Comospa Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 75

Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling

9:00AM-11:00AM: Abstract Number: 434

Factors Associated with Treatment Adherence in Rheumatoid Arthritis: A Systematic Literature Review

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 329

Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 411

Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 565

Fatigue in Primary Sjögren’s Syndrome (pSS) Is Associated with Lower Levels of Proinflammatory Cytokines: A Validation Study

Sjögren's Syndrome Poster I: Translational Research

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].